1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. Belgium >
  5. Curium Pharma Acquires Nucleis

M&A Deal Summary

Curium Pharma Acquires Nucleis

On April 10, 2025, Curium Pharma acquired life science company Nucleis

Acquisition Highlights
  • This is Curium Pharma’s 3rd transaction in the Life Science sector.
  • This is Curium Pharma’s 1st transaction in Belgium.

M&A Deal Summary
Date 2025-04-10
Target Nucleis
Sector Life Science
Buyer(s) Curium Pharma
Deal Type Add-on Acquisition

Target

Nucleis

Liège, Belgium
Nucleis is a GMP manufacturing and distribution of PET radiopharmaceutical drugs. The Company manufactures and distributes FDG in the Benelux region and offers CDMO services to third-party nuclear medicine players to produce innovative tracers. Nucleis was founded in 2017 and is based in Liège, Belgium.

Search 215,029 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Curium Pharma

Paris, France
Category Company
Founded 2017
Sector Life Science
DESCRIPTION

Curium Pharma is the largest nuclear medicine company with more than a century of industry experience. Curium develops, manufacture, and distribute world-class radiopharmaceutical products to help patients around the globe. Curium Pharma was founded in 2017 and is based in Paris, France.

DEAL STATS #
Overall 3 of 3
Sector: Life Science M&A 3 of 3
Type: Add-on Acquisition M&A Deals 3 of 3
Country: Belgium M&A 1 of 1
Year: 2025 M&A 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2024-04-08 Eczacıbaşı-Monrol

Istanbul, Turkey

Eczacıbaşı-Monrol is an innovative, international supplier of radiopharmaceuticals for diagnosis and treatment in nuclear medicine. Eczacıbaşı-Monrol is based in Istanbul, Turkey.

Buy -
Mergr

Solution for

Product

Company

Legal